Seven Eight Capital, LP Apellis Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$38.07 - $59.71 $431,751 - $677,171
-11,341 Reduced 61.5%
7,101 $272,000
Q1 2024

May 13, 2024
BUY
$55.39 - $72.47 $1.02 Million - $1.34 Million
18,442 New
18,442 $1.08 Million
Q3 2023

Nov 14, 2023
BUY
$23.65 - $89.22 $524,746 - $1.98 Million
22,188 New
22,188 $844,000
Q4 2020

Feb 09, 2021
SELL
$30.79 - $57.2 $362,367 - $673,186
-11,769 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$25.89 - $33.65 $304,699 - $396,026
11,769 New
11,769 $355,000

Others Institutions Holding APLS

# of Institutions
302
Shares Held
112M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.19B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email